C3orf19_C130022K22Rik Inhibitors
The functional activity of C3orf19_C130022K22Rik can be diminished by a collection of chemical inhibitors that specifically target signaling pathways and cellular processes potentially regulating this protein. LY 294002 and Rapamycin, both inhibitors of the PI3K/Akt pathway, could decrease the functional activity of C3orf19_C130022K22Rik by disrupting the pathway's downstream signaling which could be crucial for the protein's stability or function. Similarly, PD 98059 and U0126, by inhibiting MEK1/2, could prevent the activation of the MAPK/ERK pathway, thus potentially reducing the activity of C3orf19_C130022K22Rik if it is dependent on this signaling for its function. SB 203580's inhibition of p38 MAP kinase could lead to a decrease in C3orf19_C130022K22Rik activity if it is associated with stress response signaling mediated by p38 MAPK. Inhibition of JNK by SP600125 could similarly diminish the protein's activity by interfering with JNK-related signaling pathways.
Moreover, PP 2's inhibition of Src family tyrosine kinases and Sunitinib's broader receptor tyrosine kinase inhibition could weaken signaling cascades involving tyrosine phosphorylation, which might be critical for C3orf19_C130022K22Rik's functional role. WZ8040, a NUAK kinase inhibitor, and Gö 6976, targeting PKC, could each reduce C3orf19_C130022K22Rik activity by inhibiting kinases that potentially regulate its function. Inhibition of ROCK by Y-27632 could lead to an indirect decrease in C3orf19_C130022K22Rik activity if the protein's function is modulated by cytoskeletal dynamics controlled by ROCK signaling. Lastly, Bortezomib's role in inhibiting proteasomal degradation could indirectly affect C3orf19_C130022K22Rik by stabilizing inhibitory proteins that oversee its activity, thus providing a unique approach to diminishing its function. Collectively, these inhibitors, while diverse in their targets, present a concerted approach to dampen the activity of C3orf19_C130022K22Rik through multifaceted biochemical inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that prevents PI3K-mediated signaling. Since PI3K/Akt pathway is crucial for many proteins' stability and function, inhibition by LY 294002 would diminish C3orf19_C130022K22Rik activity if it is PI3K/Akt pathway-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. By inhibiting MEK, PD 98059 could reduce ERK pathway activity, potentially diminishing C3orf19_C130022K22Rik function if it relies on MAPK/ERK signaling for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. Inhibition of the p38 MAPK pathway by SB 203580 could lead to decreased activity of C3orf19_C130022K22Rik if it is involved in cellular responses mediated by p38 MAPK. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A selective Src family tyrosine kinase inhibitor. By inhibiting Src kinase, PP 2 could reduce tyrosine phosphorylation-dependent signaling pathways, which might diminish C3orf19_C130022K22Rik activity if it is regulated by Src kinase signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor known to affect the PI3K/Akt/mTOR pathway. Rapamycin could diminish C3orf19_C130022K22Rik activity if the protein is involved in processes regulated by mTOR, such as growth and proliferation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of both MEK1 and MEK2, which could reduce ERK pathway signaling. If C3orf19_C130022K22Rik activity is mediated by the ERK pathway, U0126 could diminish its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor that selectively inhibits c-Jun N-terminal kinase (JNK). Inhibition of JNK by SP600125 could diminish C3orf19_C130022K22Rik function if it plays a role in JNK-dependent signaling pathways. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
A selective inhibitor of the NUAK family of kinases. By inhibiting related kinases, WZ4003 could diminish C3orf19_C130022K22Rik activity if it is regulated by NUAK signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of the Rho-associated protein kinase (ROCK). Y-27632 inhibition of ROCK could theoretically diminish the function of C3orf19_C130022K22Rik if the protein's activity is modulated by ROCK signaling. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
A potent inhibitor of protein kinase C (PKC). Since PKC is involved in numerous signaling cascades, inhibition by Gö 6976 could diminish C3orf19_C130022K22Rik activity if PKC pathways modulate its function. | ||||||